The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

A new generation of obesity drugs – such as Novo Nordisk A/S’ Wegovy and Eli Lilly and Company’s Zepbound – is changing the perception of obesity as a multifaceted illness that requires ...

The company has also taken strategic steps to improve access; the company has launched a single-dose 2.5 mg and 5 mg Zepbound vials in the U.S. exclusively through LillyDirect for less than half ...

Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI) of ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Per the partial data released from that phase 3b clinical trial, over 72 weeks of once-weekly treatment with either Zepbound or Wegovy, patients taking Zepbound lost 20.2% of their weight on ...

Interchangeable knitting needles have revolutionized knitting for everyone, from beginners to experts. These versatile needles enable you to adjust the needle ends and cables to create any size or ...

Expanding upon their ongoing collaboration, WILDSIDE Yohji Yamamoto and NEEDLES have come together to reinterpret NEEDLES’ classic Cowboy jacket and pants. The Cowboy jacket features a snap ...

Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens ...

Eli Lilly pre-announced the following drug numbers for Q4: Mounjaro — $3.5 billion, up from $3.1 billion in Q3 Zepbound — $1.9 billion, up from $1.26 billion in Q3. The biopharma reported ...